Fresenius Medical Care (NYSE:FMS - Get Free Report) released its quarterly earnings data on Tuesday. The company reported $0.48 earnings per share for the quarter, topping analysts' consensus estimates of $0.41 by $0.07, Zacks reports. Fresenius Medical Care had a return on equity of 6.04% and a net margin of 3.43%.
Fresenius Medical Care Trading Up 0.7 %
NYSE FMS traded up $0.15 during trading hours on Tuesday, reaching $23.46. The company had a trading volume of 203,911 shares, compared to its average volume of 248,286. Fresenius Medical Care has a 1-year low of $17.93 and a 1-year high of $25.25. The stock has a market capitalization of $13.77 billion, a P/E ratio of 19.39, a price-to-earnings-growth ratio of 0.76 and a beta of 0.93. The stock has a 50-day moving average of $23.39 and a 200 day moving average of $21.77. The company has a current ratio of 1.37, a quick ratio of 1.02 and a debt-to-equity ratio of 0.42.
Analysts Set New Price Targets
Several brokerages have recently weighed in on FMS. Berenberg Bank assumed coverage on shares of Fresenius Medical Care in a research report on Wednesday, November 6th. They set a "buy" rating and a $25.60 price target on the stock. Bank of America upgraded shares of Fresenius Medical Care from an "underperform" rating to a "neutral" rating in a report on Monday, December 2nd. Truist Financial raised their price target on shares of Fresenius Medical Care from $23.00 to $25.00 and gave the stock a "hold" rating in a report on Monday, January 6th. Finally, StockNews.com upgraded Fresenius Medical Care from a "hold" rating to a "strong-buy" rating in a report on Wednesday, February 5th.
Read Our Latest Report on Fresenius Medical Care
About Fresenius Medical Care
(
Get Free Report)
Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.
Featured Stories
Before you consider Fresenius Medical Care, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Fresenius Medical Care wasn't on the list.
While Fresenius Medical Care currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
